INTRODUCTION: Dyspnea is common among lung cancer patients. As most studies of dyspnea have reviewed patients with active cancer or immediately after treatment, its prevalence during the longer-term period once treatment has been completed is not well characterized. This study quantifies the prevalence of dyspnea among lung cancer survivors and identifies potential correlates that may be amenable to intervention. METHODS: Cross-sectional survey of 342 patients with disease-free, stage I, non-small cell lung cancer, assessed 1 to 6 years after surgical resection. Dyspnea was quantified using the Baseline Dyspnea Index. Any moderate/strenuous physical activity was measured using the Godin Leisure-Time Exercise Questionnaire. Mood disorder symptoms were assessed using the Hospital Anxiety and Depression Scale. Multiple regression analyses were used to examine demographic, medical, and health-related correlates of dyspnea. RESULTS: Mean age was 68.9 years. Average predicted preoperative forced expiratory volume in 1 second was 89.0%. Current dyspnea, defined by a Baseline Dyspnea Index score of 9 or less, existed among 205 (60%) individuals. For 133 (65%) of these patients, dyspnea was absent preoperatively. Multivariate correlates of current dyspnea included preoperative dyspnea (odds ratio [OR] = 5.31), preoperative diffusing capacity (OR = 0.98), lack of moderate/strenuous physical activity (OR = 0.41), and the presence of clinically significant depression symptoms (OR = 4.10). CONCLUSIONS: Dyspnea is common 1 to 6 years after lung cancer resection, and is associated with the presence of preoperative dyspnea, reduced diffusing capacity, clinically significant depression symptoms, and lack of physical activity. Further research is needed to test whether strategies that identify and treat patients with these conditions attenuate dyspnea among lung cancer survivors.
INTRODUCTION:Dyspnea is common among lung cancerpatients. As most studies of dyspnea have reviewed patients with active cancer or immediately after treatment, its prevalence during the longer-term period once treatment has been completed is not well characterized. This study quantifies the prevalence of dyspnea among lung cancer survivors and identifies potential correlates that may be amenable to intervention. METHODS: Cross-sectional survey of 342 patients with disease-free, stage I, non-small cell lung cancer, assessed 1 to 6 years after surgical resection. Dyspnea was quantified using the Baseline Dyspnea Index. Any moderate/strenuous physical activity was measured using the Godin Leisure-Time Exercise Questionnaire. Mood disorder symptoms were assessed using the Hospital Anxiety and Depression Scale. Multiple regression analyses were used to examine demographic, medical, and health-related correlates of dyspnea. RESULTS: Mean age was 68.9 years. Average predicted preoperative forced expiratory volume in 1 second was 89.0%. Current dyspnea, defined by a Baseline Dyspnea Index score of 9 or less, existed among 205 (60%) individuals. For 133 (65%) of these patients, dyspnea was absent preoperatively. Multivariate correlates of current dyspnea included preoperative dyspnea (odds ratio [OR] = 5.31), preoperative diffusing capacity (OR = 0.98), lack of moderate/strenuous physical activity (OR = 0.41), and the presence of clinically significant depression symptoms (OR = 4.10). CONCLUSIONS:Dyspnea is common 1 to 6 years after lung cancer resection, and is associated with the presence of preoperative dyspnea, reduced diffusing capacity, clinically significant depression symptoms, and lack of physical activity. Further research is needed to test whether strategies that identify and treat patients with these conditions attenuate dyspnea among lung cancer survivors.
Authors: Linda Sarna; Mary E Cooley; Jean K Brown; Cynthia Chernecky; David Elashoff; Jenny Kotlerman Journal: Am J Crit Care Date: 2008-09 Impact factor: 2.228
Authors: Christopher M Callahan; Frederick W Unverzagt; Siu L Hui; Anthony J Perkins; Hugh C Hendrie Journal: Med Care Date: 2002-09 Impact factor: 2.983
Authors: Jennifer A Shin; Jesse D Kosiba; Lara Traeger; Joseph A Greer; Jennifer S Temel; William F Pirl Journal: J Pain Symptom Manage Date: 2014-04-21 Impact factor: 3.612
Authors: Paul Krebs; Elliot J Coups; Marc B Feinstein; Jack E Burkhalter; Richard M Steingart; Amy Logue; Bernard J Park; Jamie S Ostroff Journal: J Cancer Surviv Date: 2011-07-02 Impact factor: 4.442
Authors: Amy E Lowery; Paul Krebs; Elliot J Coups; Marc B Feinstein; Jack E Burkhalter; Bernard J Park; Jamie S Ostroff Journal: Support Care Cancer Date: 2013-09-10 Impact factor: 3.603
Authors: Vinicius Cavalheri; Chris Burtin; Vittoria R Formico; Mika L Nonoyama; Sue Jenkins; Martijn A Spruit; Kylie Hill Journal: Cochrane Database Syst Rev Date: 2019-06-17
Authors: Errol J Philip; Elliot J Coups; Marc B Feinstein; Bernard J Park; Donna J Wilson; Jamie S Ostroff Journal: Support Care Cancer Date: 2013-10-05 Impact factor: 3.603
Authors: James Huang; Amy E Logue; Jamie S Ostroff; Bernard J Park; Mary McCabe; David R Jones; Manjit S Bains; Nabil P Rizk; Mark G Kris; Valerie W Rusch Journal: Ann Thorac Surg Date: 2014-07-31 Impact factor: 4.330